How best to address breast pain in nonbreastfeeding women

,; ,; ,; ,

Applied Evidence

How best to address breast pain in nonbreastfeeding women

J Fam Pract. 2019 September;68(7):379-382,384-388

PDF Download

References

1. Salzman B, Fleegle S, Tully AS. Common breast problems. Am Fam Physician. 2012;86:343-349.

2. Chetlen AL, Kapoor MM, Watts MR. Mastalgia: imaging work-up appropriateness. Acad Radiol. 2017;24:345-349.

3. Expert Panel on Breast Imaging: Jokich PM, Bailey L, D’Orsi C, et al. ACR Appropriateness Criteria Breast Pain. J Am Coll Radiol. 2017;14:S25-S33.

4. Arslan M, Küçükerdem HS, Can H, et al. Retrospective analysis of women with only mastalgia. J Breast Health. 2016;12:151-154.

5. Smith RL, Pruthi S, Fitzpatrick LA. Evaluation and management of breast pain. Mayo Clin Proc. 2004;79:353-372.

6. Mansel RE. ABC of breast diseases. Breast pain. BMJ. 1994;309:866-868.

7. Ader DN, South-Paul J, Adera T, et al. Cyclical mastalgia: prevalence and associated health and behavioral factors. J Psychosom Obstet Gynaecol. 2001;22:71-76.

8. Iddon J, Dixon JM. Mastalgia. BMJ. 2013;347:f3288.

9. Eren T, Aslan A, Ozemir IA, et al. Factors effecting mastalgia. Breast Care (Basel). 2016;11:188-193.

10. Pearlman MD, Griffin JL. Benign breast disease. Obstet Gynecol. 2010;116:747-758.

11. Gateley CA, Mansel RE. The Cardiff Breast Score. Br J Hosp Med. 1991;45:16.

12. Michigan Medicine. University of Michigan. Common breast problems: guidelines for clinical care. https://www.med.umich.edu/1info/FHP/practiceguides/breast/breast.pdf. Updated June 2013. Accessed September 3, 2019.

13. Millet AV, Dirbas FM. Clinical management of breast pain: a review. Obstet Gynecol Surv. 2002;57:451-461.

14. American College of Radiology. ACR Appropriateness Criteria: Breast Pain. https://acsearch.acr.org/docs/3091546/Narrative/. Revised 2018. Accessed July 2, 2019.

15. American College of Radiology. ACR Appropriateness Criteria: Palpable Breast Masses. https://acsearch.acr.org/docs/69495/Narrative/. Revised 2016. Accessed September 3, 2019.

16. Loving VA, DeMartini WB, Eby PR, et al. Targeted ultrasound in women younger than 30 years with focal breast signs or symptoms: outcomes analyses and management implications. AJR Am J Roentgenol. 2010;195:1472-1477.

17. Molckovsky A, Fitzgerald B, Freedman O, et al. Approach to inflammatory breast cancer. Can Fam Physician. 2009;55:25-31.

18. Ammari FF, Yaghan RJ, Omari AK. Periductal mastitis: clinical characteristics and outcome. Saudi Med J. 2002;23:819-822.

19. Lannin DR. Twenty-two year experience with recurring subareolar abscess and lactiferous duct fistula treated by a single breast surgeon. Am J Surg. 2004;188:407-410.

20. Wilson JP, Massoll N, Marshall J, et al. Idiopathic granulomatous mastitis: in search of a therapeutic paradigm. Am Surg. 2007;73:798-802.

21. Bouton ME, Jayaram L, O’Neill PJ, et al. Management of idiopathic granulomatous mastitis with observation. Am J Surg. 2015;210:258-262.

22. Olawaiye A, Withiam-Leitch M, Danakas G, et al. Mastalgia: a review of management. J Reprod Med. 2005;50:933-939.

23. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Gynecology. Practice Bulletin No. 164: Diagnosis and management of benign breast disorders. Obstet Gynecol. 2016;127:e141-e156.

24. Mirghafourvand M, Mohammad-Alizadeh-Charandabi S, Ahmadpour P, et al. Effects of Vitex agnus and flaxseed on cyclic mastalgia: a randomized controlled trial. Complement Ther Med. 2016;24:90-95.

25. Vaziri F, Zamani Lari M, Sansami Dehaghani A, et al. Comparing the effects of dietary flaxseed and omega-3 fatty acids supplement on cyclical mastalgia in Iranian women: a randomized clinical trial. Int J Fam Med. 2014;2014:174532.

26. Sohrabi N, Kashanian M, Ghafoori SS, et al. Evaluation of the effect of omega-3 fatty acids in the treatment of premenstrual syndrome: “a pilot trial”. Complement Ther Med. 2013;21:141-146.

27. McFayden IJ, Chetty U, Setchell KD, et al. A randomized double blind-cross over trial of soya protein for the treatment of cyclical breast pain. Breast. 2000;9:271-276.

28. Pruthi S, Wahner-Roedler DL, Torkelson CJ, et al. Vitamin E and evening primrose oil for management of cyclical mastalgia: a randomized pilot study. Altern Med Rev. 2010;15:59-67.

29. Halaska M, Raus K, Beles P, et al. Treatment of cyclical mastodynia using an extract of Vitex agnus castus: results of a double-blind comparison with a placebo. Ceska Gynekol. 1998;63:388-392.

30. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective randomised placebo controlled study. BMJ. 2001;322:134-137.

31. Goyal A. Breast pain. BMJ Clin Evid. 2011;2011:0812.

32. Maddox PR, Harrison BJ, Mansel RE. Low-dose danazol for mastalgia. Br J Clin Pract Suppl. 1989;68:43-47.

33. Ahmadinejad M, Delfan B, Haghdani S, et al. Comparing the effect of diclofenac gel and piroxicam gel on mastalgia. Breast J. 2010;16:213-214.

34. Kontostolis E, Stefanidis K, Navrozoglou I, et al. Comparison of tamoxifen with danazol for treatment of cyclical mastalgia. Gynecol Endocrinol. 1997;11:393-397.

35. Marjoribanks J, Brown J, O’Brien PM, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013;(6):CD001396. doi: 10.1002/14651858.CD001396.pub3.

36. Nappi C, Affinito P, Di Carlo C, et al. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease. J Endocrinol Invest. 1992;15:801-806.

37. Mansel RE, Goyal A, Preece P, et al. European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol. 2004;191:1942-1949.

38. Colak T, Ipek T, Kanik A, et al. Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment. J Am Coll Surg. 2003;196:525-530.

39. Goyal A. Breast pain. Am Fam Physician. 2016;93:872-873.

40. Srivastava A, Mansel RE, Arvind N, et al. Evidence-based management of mastalgia: a meta-analysis of randomised trials. Breast. 2007;16:503-512.

41. US Preventive Services Task Force. Breast cancer: Screening. Release date: January 2016. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-screening1. Accessed August 13, 2019.

Oral contraceptives. For women who use oral contraceptive pills and experience cyclic breast pain, continuous dosing (skipping the pill-free week) or using a lower dose of estrogen may improve symptoms. Postmenopausal women with mastalgia that developed with initiation of hormone therapy may benefit from discontinuing hormone therapy or decreasing the estrogen dose; however, there are no RCTs to offer conclusive evidence of the effectiveness of these interventions.¹⁰

Danazol. Women with severe mastalgia that does not respond to more benign therapies may require hormone therapy. As with all symptom management, it is imperative to engage the patient in a shared decision-making conversation about the risks and benefits of this treatment strategy. Women must be able to balance the potential adverse effects of agents such as danazol and tamoxifen with the need to alleviate pain and improve quality of life.

Oral NSAIDs are often recommended as first-line treatment for mastalgia.

Danazol is the only medication FDA-approved for the treatment of mastalgia. Danazol is an androgen that blocks the release of other gonadotropins to limit hormonal stimulation of breast tissue. One RCT demonstrated that danazol (100 mg bid) reduces breast pain in 60% to 90% of women, although adverse effects often limit utility.⁴⁰ Adverse effects of danazol include weight gain, hot flashes, deepening of the voice, hirsutism, menorrhagia or amenorrhea, muscle cramps, and androgenic effects on a fetus.^8,31,40 Danazol may be best used cyclically during the luteal phase of the menstrual cycle to limit these adverse effects with reduction of the dose to 100 mg/d after relief of symptoms.^31,40

Tamoxifen, a selective estrogen receptor modulator, has been shown to reduce breast pain in 80% to 90% of women, although it is not indicated for mastalgia.⁴⁰Tamoxifen may cause endometrial thickening, hot flashes, menstrual irregularity, venous thromboembolism, and teratogenicity. The 10 mg/d dose appears to be as effective at improving symptoms as the 20 mg/d dose with fewer adverse effects.^8,31,40

In a head-to-head randomized trial, tamoxifen was superior to danazol for relief of breast pain with fewer adverse effects.³⁴ Experts recommend limiting use of tamoxifen and danazol to 3 to 6 months. Neither of these drugs is considered safe in pregnancy.

Continue to: Bromocriptine